Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

USFDA Gives Nod For Riluzole Tablets To Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd's Glenmark Generics-Business Line


Thursday, 20 Jun 2013 08:00pm EDT 

Business Line reported that Sun Pharmaceutical Industries Ltd and Glenmark Generics have got approval from US health regulator to sell generic versions of nervous system disorder treatment drug Riluzole. As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg. Riluzole is indicated for treatment of amyotrophic lateral sclerosis. 

Company Quote

809.25
-2.75 -0.34%
19 Dec 2014